These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22481009)

  • 1. Limitations and biases of the Surveillance, Epidemiology, and End Results database.
    Park HS; Lloyd S; Decker RH; Wilson LD; Yu JB
    Curr Probl Cancer; 2012; 36(4):216-24. PubMed ID: 22481009
    [No Abstract]   [Full Text] [Related]  

  • 2. Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance.
    Park HS; Lloyd S; Decker RH; Wilson LD; Yu JB
    Curr Probl Cancer; 2012; 36(4):183-90. PubMed ID: 22481006
    [No Abstract]   [Full Text] [Related]  

  • 3. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview.
    Scosyrev E; Messing J; Noyes K; Veazie P; Messing E
    Urol Oncol; 2012; 30(2):126-32. PubMed ID: 20363162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the Surveillance, Epidemiology, and End Results database to investigate rare cancers, second malignancies, and trends in epidemiology, treatment, and outcomes.
    Lloyd S; Park HS; Decker RH; Wilson LD; Yu JB
    Curr Probl Cancer; 2012; 36(4):191-9. PubMed ID: 22495057
    [No Abstract]   [Full Text] [Related]  

  • 5. NCI Surveillance, Epidemiology & End Results (SEER) registry. Foreword.
    Johnstone PA
    Curr Probl Cancer; 2012; 36(4):182. PubMed ID: 22824197
    [No Abstract]   [Full Text] [Related]  

  • 6. The surveillance, epidemiology, and end results program: a national resource.
    Hankey BF; Ries LA; Edwards BK
    Cancer Epidemiol Biomarkers Prev; 1999 Dec; 8(12):1117-21. PubMed ID: 10613347
    [No Abstract]   [Full Text] [Related]  

  • 7. A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities.
    Sun M; Trinh QD
    BJU Int; 2016 Apr; 117(4):551-2. PubMed ID: 26190064
    [No Abstract]   [Full Text] [Related]  

  • 8. NCI SEER public-use data: applications and limitations in oncology research.
    Yu JB; Gross CP; Wilson LD; Smith BD
    Oncology (Williston Park); 2009 Mar; 23(3):288-95. PubMed ID: 19418830
    [No Abstract]   [Full Text] [Related]  

  • 9. Checking up on the surveillance, epidemiology, and end results program.
    Henson DE; Albores-Saavedra J
    J Natl Cancer Inst; 2004 Jul; 96(14):1050-1. PubMed ID: 15265959
    [No Abstract]   [Full Text] [Related]  

  • 10. Limitations of claims and registry data in surgical oncology research.
    Nathan H; Pawlik TM
    Ann Surg Oncol; 2008 Feb; 15(2):415-23. PubMed ID: 17987343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation in research and social context: the case of population-based cancer registration, surveillance, and research.
    McLaughlin RH
    Am J Bioeth; 2008 Oct; 8(10):41-2. PubMed ID: 19003707
    [No Abstract]   [Full Text] [Related]  

  • 12. Reducing Bias in Oncology Research: The End of the Radiation Variable in the Surveillance, Epidemiology, and End Results (SEER) Program.
    Walker GV; Grant SR; Jagsi R; Smith BD
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):302-303. PubMed ID: 28871979
    [No Abstract]   [Full Text] [Related]  

  • 13. Dewey defeats Truman and cancer statistics.
    Friedenson B
    J Natl Cancer Inst; 2009 Aug; 101(16):1157. PubMed ID: 19561316
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative Effectiveness Research and the Surveillance, Epidemiology, and End Results database: what is Comparative Effectiveness Research (CER) and why is it important?
    Yu JB; Lloyd S; Decker RH; Wilson LD; Park HS
    Curr Probl Cancer; 2012; 36(4):208-15. PubMed ID: 22481005
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparing breast cancer case identification using HMO computerized diagnostic data and SEER data.
    Rolnick SJ; Hart G; Barton MB; Herrinton L; Flores SK; Paulsen KJ; Husson G; Harris EL; Geiger AM; Elmore JG; Fletcher SW
    Am J Manag Care; 2004 Apr; 10(4):257-62. PubMed ID: 15124502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies.
    Harlan LC; Hankey BF
    J Clin Oncol; 2003 Jun; 21(12):2232-3. PubMed ID: 12805320
    [No Abstract]   [Full Text] [Related]  

  • 17. Misclassification of hospital volume with Surveillance, Epidemiology, and End Results Medicare data.
    Hollenbeck BK; Hong Ji ; Zaojun Ye ; Birkmeyer JD
    Surg Innov; 2007 Sep; 14(3):192-8. PubMed ID: 17928618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer health disparities among Indian and Pakistani immigrants in the United States: a Surveillance, Epidemiology, and End Results-based study from 1988 to 2003.
    Hossain A; Sehbai A; Abraham R; Abraham J
    Cancer; 2008 Sep; 113(6):1423-30. PubMed ID: 18696716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction models, nomograms, and staging validation with the Surveillance, Epidemiology, and End Results database: using Surveillance, Epidemiology and End Results (SEER) program to create prediction models.
    Lloyd S; Park HS; Wilson LD; Decker RH; Yu JB
    Curr Probl Cancer; 2012; 36(4):200-7. PubMed ID: 22481008
    [No Abstract]   [Full Text] [Related]  

  • 20. Life risk assessment in cancer: a guide to using the surveillance, epidemiology, and end results (SEER) program.
    Rigatti SJ
    J Insur Med; 2010; 42(1):18-29. PubMed ID: 21290996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.